Loading…

PG545 alleviates diabetic retinopathy by promoting retinal Müller cell autophagy to inhibit the inflammatory response

Diabetic retinopathy (DR), a major cause of blindness in working-age people, is attributed to the inflammatory response of retinal Müller cells (RMCs). The heparanase inhibitor PG545 plays proautophagic and anti-inflammatory roles. Intraperitoneal injection of PG545 at a dose of 20 mg/kg/d clearly r...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical and biophysical research communications 2020-10, Vol.531 (4), p.452-458
Main Authors: Wang, Ying, Liu, Xiaojuan, Zhu, Linling, Li, Wendie, Li, Zhizhe, Lu, Xiting, Liu, Jie, Hua, Wenjuan, Zhou, Yamei, Gu, Yonghui, Zhu, Manhui
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diabetic retinopathy (DR), a major cause of blindness in working-age people, is attributed to the inflammatory response of retinal Müller cells (RMCs). The heparanase inhibitor PG545 plays proautophagic and anti-inflammatory roles. Intraperitoneal injection of PG545 at a dose of 20 mg/kg/d clearly reduced diabetes-induced body weight changes and fasting blood glucose levels in mice. PG545 also mitigated the reduction in retinal thickness and the formation of microaneurysms by promoting autophagy to inhibit the inflammatory response. In vitro, PG545 stimulated autophagy to downregulate the inflammatory response in high glucose-induced primary adult mouse RMCs. These data suggest that PG545 mitigates DR by promoting RMC autophagy to inhibit the inflammatory response. •PG545 facilitates the autophagy in primary mouse retinal Müller cells (RMCs) under high glucose (HG) conditions.•PG545 inhibits inflammatory response via promoting autophagy in mouse MRCs under HG conditions.•PG545 mitigates the reduce of retinal thickness and the formation of microaneurysms in mouse diabetic model.
ISSN:0006-291X
1090-2104
DOI:10.1016/j.bbrc.2020.07.134